NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Fortress Biotech, Inc. (FBIO) Stock Analysis

Fortress Biotech, Inc. (FBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FBIO

$2.72

+$0.01 (+0.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FBIO with… →

FBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$2.68
Previous Close
$2.71
Day's Range
2.68–2.74
52-Week Range
2.18–4.53
Volume
168.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$90.71M
P/E Ratio
0.98
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.32
EPS (ttm)Profit attributable to each share over the last twelve months.
2.78
Financials (FY)
Revenue (FY)
$63.26M+9.69%
Net Income (FY)
$6.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
163.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
33.35M
1-Year Return
−4.23%
Dividend and dates
Avg Volume
602.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−25.68%
2025+80.30%
2024−32.56%
2023−69.60%
2022−73.60%
2021−21.14%
2020+23.35%
2019+198.84%
2018−78.45%
2017+47.78%
2016 (partial year)−10.00%

As of September 4, 2026.

FBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$63.26M$6.82M10.8%
2024$57.68M−$46.00M−79.8%
2023$84.51M−$60.64M−71.7%
2022$75.74M−$86.58M−114.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$63.26M$42.34M−$70.22M$6.82M10.8%
2024$57.68M$36.80M−$111.24M−$46.00M−79.8%
2023$84.51M$61.62M−$139.20M−$60.64M−71.7%
2022$75.74M$44.97M−$203.56M−$86.58M−114.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricFBIOBiotechnology medianvs median
P/E0.9812.570.1x the median
P/S ratio1.3215.260.1x the median
Profit margin163.32%0.00%163.3 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Fortress Biotech, Inc. (FBIO) carries a market capitalisation of $90.71M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 78 employees.

The most recent close on file for FBIO is $2.72, dated September 4, 2026. That is +$0.01 (+0.37%) against the previous close. The 52-week range on file runs from $2.18 to $4.53. The latest close sits 24.77% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $63.26M. Against the prior fiscal year total of $57.68M, that is a change of +9.69%. Net income for the same year was $6.82M. Profit margin runs at 163.32%. That is 163.3 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 2.78.

Across the 4 fiscal years on file, revenue moves from $75.74M in 2022 to $63.26M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 0.98. That is 0.1 times the Biotechnology median of 12.57. The price-to-sales ratio is 1.32. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.19. Daily returns over the trailing 10 years annualize to a volatility of 85.64%. Over the trailing twelve months the price has returned −4.23%. Measured over 10 years, that is −23.81% a year compounded.

Growth & Income

The record shows no dividend for FBIO.

So far in 2026 the price is −25.68%. The strongest complete calendar year on file is 2019 at +198.84%; the weakest is 2018 at −78.45%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Fortress Biotech, Inc. (FBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fortress Biotech, Inc. FBIO $90.71M 1.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Fortress Biotech, Inc. trades at a P/E of 1.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Fortress Biotech, Inc.

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Visit website →